The Influence of Angiographic Endpoints on the Outcome of Lipid Intervention Studies

Abstract

The aims of this study were to evaluate the influence of different coronary angiographic endpoints on the outcome of lipid intervention studies and to formulate a proposal for angiographic endpoint standardization.

In recent angiographic intervention studies a confusing diversity in angiographic endpoints has been used to determine the outcome. In addition, differences in study populations (eg, bypass patients included or not) could influence results. This makes comparisons between studies cumbersome and raises the question to what extent the results of various studies may be subject to the selection of angiographic endpoints.

The investigators compared three frequently used endpoints (mean segment diameter, minimum obstruction diameter, and % stenosis) in a group of 505 patients who had just finished a trial designed to assess the effect of cholesterol lowering by pravastatin. To exclude a potential bias this analysis was carried out at the time that the study was still blinded. (continued on next page)

They found poor intercorrelation coefficients for mean segment diameter calculated in different ways, ranging from 0.55 to 0.95, dependent on inclusion or exclusion of segments influenced by coronary angioplasty or bypass grafting and on whether or not a value of 0 was assumed for occluded segments and segments distal to occlusions. The correlation between mean segment diameter and minimum obstruction diameter was 0.79; between minimum obstruction diameter and % stenosis, 0.85; and between mean segment diameter and % stenosis, only 0.64.

Different endpoints sometimes correlate poorly. This may lead to differences in results of angiographic intervention trials. The authors propose standardization by (1) using both mean segment diameter and minimum obstruction diameter as endpoints and (2) excluding from the primary analysis segments influenced by mechanical interven tions.

Get full access to this article

View all access options for this article.

References

Brensike JF , Levy RI , Kelsey SF , et al: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI type II coronary intervention study . Circulation 69:313-324, 1984.

Arntzenius AC , Kromhout D. , Barth JD , et al: Diet, lipoproteins, and the progression of coronary atherosclerosis. N Engl J Med 312:805-811, 1985.

Blankenhorn DH , Nessim SA , Johnson RL , et al: Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257:3233-3240, 1987.

Buchwald H. , Varco RL , Matts JP , et al: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 323:946-955, 1990.

Brown G. , Albers JJ , Fisher LD , et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:1298-1298, 1990 .

Kane JP , Malloy MJ , Ports TA , et al: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264:3007-3012, 1990.

Ornish D. , Brown SE , Scherwitz LW , et al: Can lifestyle changes reverse coronary heart disease? Lancet 336:129-133, 1990.

Schuler G. , Hambrecth R. , Schlierf G. , et al: Regular physical exercise and low-fat diet: Effects on progression of coronary artery disease. Circulation 86:1-11, 1992.

Watts GF , Lewis B. , Brunt Jnh , et al: Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339:563-569, 1992.

10.

Pitt B. , Ellis SG , Mancini Gbj , et al: Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol 72:31-35, 1993.

11.

Blankenhorn DH , Azen SP , Kramsch DM , et al: The Monitored Atherosclerosis Regression Study (MARS): coronary angiographic changes with lovastatin therapy. Ann Intern Med 119:969-976, 1993.

12.

Dumont JM , on behalf of the MAAS Research Group. Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: Design, baseline characteristics, and progress of the Multicenter Antiatheroma Study (MAAS). Controlled Clin Trials 14:209-228, 1993.

13.

Waters D. , Higginson L. , Gladstone P. , et al: Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89:959-968, 1994.

14.

Reiber Jhc , Jukema JW , Hekking E. , et al: Catheter sizes for quantitative coronary arteriography. Cathet Cardiovasc Diagn (in press).

15.

Reiber Jhc , Zwet PMJ van der , Land CD von , et al: Quantitative coronary arteriography: Equipment and technical requirements. In: Advances in Quantitative Coronary Arteriography , ed. by Reiber JHC , Serruys PW. Dordrecht: Kluwer Academic Publishers, 1992, pp 75-111.

16.

Austen WG , Edwards JE , Frye RL , et al: A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery disease, council on cardiovascular surgery, American Heart Association. Circulation 51:6-34, 1975.

17.

Feyter PJ de , Vos J. , Reiber Jhc , et al: Value and limitations of quantitative coronary angiography to assess progression or regression of coronary atherosclerosis . In: Advances in Quantitative Coronary Arteriography, ed. by Reiber JHC , Serruys PW. Dordrecht: Kluwer Academic Publishers, 1992, pp 255-271.

18.

Lespérance J. , Waters D. : Measuring progression and regression of coronary atherosclerosis in clinical trials: Problems and progress. Int J Card Imag 8:165-173, 1992.